Organomics is focused on developing innovative therapeutics for patients suffering from complex brain diseases. The company utilizes advanced automated microfluidic brain-on-chip technology, which allows for the characterization of pharmacological responses in human tissues. This technology is pivotal in testing the efficacy of potential drug candidates, enabling a more efficient and effective drug discovery process. By leveraging this cutting-edge platform, Organomics aims to accelerate the development of novel treatments that can address the unique challenges posed by elusive neurological conditions.

Founded in 2021 by a team of experts with diverse backgrounds in tissue models, microfabrication, and automation, Organomics is committed to pushing the boundaries of research in the pharmaceutical field. The founders, who initially collaborated at the University of California - Santa Cruz, have created a robust research platform designed to facilitate high-velocity drug discovery. This collaborative effort underscores the company's mission to bring revolutionary technologies to clinical applications, ultimately improving therapeutic options for patients with brain diseases.

United States

The future of preclinical drug discovery is engineered tissue. The founders of OrganOmics have developed cutting-edge, live human brain tissue models derived from stem cells. They have partnered with the neurosurgeons to source patient-derived cancer tissue to induce a realistic cancer pathology. Their patented microfluidic platform automates the assay, detailing drug responses of thousands of tissues generating high-content data. This vast, cellular response data is processed through artificial intelligence to predict the clinical outcomes of each candidate drug.

Organomics

Company Details